Colorado hospitals are testing a new approach to one of the most frustrating problems in addiction medicine: patients who start methadone treatment during a hospital stay but never make it to a clinic after discharge.
For decades, federal rules required anyone seeking outpatient methadone for opioid use disorder to physically show up at a licensed opioid treatment program (OTP) to complete an intake. That meant hospitalized patients in Colorado and across the country could receive methadone during their stay, but then had to independently get themselves to a clinic after discharge to continue treatment. Facing withdrawal, lacking transportation, or dealing with untreated mental illness, most never made it. Under the old system, only about 40% of patients referred to an OTP at discharge actually linked to one.
A 2024 update to federal OTP regulations changed that. For the first time, non-OTP clinicians, including hospital-based addiction medicine doctors, can now complete the medical evaluation required for a federally compliant OTP intake. In practical terms, that means a patient hospitalized after an overdose or infection can be formally enrolled in a methadone program before they leave their hospital bed. Early research suggests the difference is dramatic: when patients completed an in-hospital OTP intake, 77% linked to ongoing treatment afterward.
To test whether Colorado hospitals can reliably operationalize that approach, researchers have secured a $709,085 NIH grant to run an implementation trial across four hospitals. The study will train hospital-based addiction clinicians, build the workflows needed to complete in-hospital intakes, and measure whether structured support improves the rate at which patients actually make it into ongoing care.
The stakes are significant. Colorado recorded more than 2,000 drug overdose deaths in 2023, the vast majority involving fentanyl, after the state's overdose rate roughly tripled between 2019 and 2022. Nationally, an estimated 7.6 million people have opioid use disorder, but fewer than 5% receive methadone treatment, a medication that, when taken regularly, is associated with a 50% reduction in mortality. The gap between how effective the treatment is and how few people receive it has long frustrated clinicians and public health officials alike.
Colorado has a growing hospital-based addiction medicine workforce, particularly at University of Colorado-affiliated and Denver Health facilities, making it a natural testing ground. Similar efforts to reach patients where they already are have emerged elsewhere in the country, including Rhode Island's prison-based methadone model, which has drawn national attention for its approach to closing treatment gaps in high-risk populations.
The trial uses a randomized design intended to generate evidence that could be scaled to hospitals nationally. Results will help determine whether the federal regulatory change, significant on paper, can translate into measurable reductions in the number of Coloradans cycling in and out of hospitals without ever getting sustained treatment.
